30 Jul 2024 --- Galderma releases its financial results for the first half of 2024, with record net sales of US$2.2 billion and growth of 10.8%. This was announced next to the completion of its European decentralized procedure for Relfydess, which treats face wrinkles.Relfydess is designed to temporarily improve the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has a significant psychological impact on the patient.
